Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Maxpro Ventures is a biomedical technology investment firm established in 2013 and headquartered in Taipei, Taiwan. The firm focuses on identifying and investing in companies that develop innovative drugs, devices, diagnostics, and services aimed at addressing unmet medical needs. Maxpro Ventures invests globally across the healthcare industry, supporting early-stage startups as well as late-stage multinational corporations.
Since its inception, Maxpro Ventures has built a diverse portfolio of 34 companies, demonstrating its commitment to advancing healthcare solutions. The firm has established a reputation for its strategic guidance and capital support, which accelerates the development of its portfolio companies. The team comprises experienced professionals with advanced degrees in relevant fields, enhancing their ability to provide valuable insights and support to founders.
Maxpro Ventures invests in breakthrough biomedical technology companies, primarily focusing on next-generation cell and gene therapies, biologic drugs, medical devices, diagnostics, and healthcare services. The firm operates across various investment stages, including pre-seed, seed, Series A, Series B, Series C, and growth equity. This broad investment strategy allows Maxpro Ventures to engage with a wide range of companies, from nascent startups to established players in the healthcare sector.
The firm seeks to partner with founders who are developing innovative solutions to pressing medical challenges. Maxpro Ventures provides both capital and strategic guidance to accelerate the development of its portfolio companies, ensuring they have the resources and expertise needed to succeed in a competitive landscape.
Maxpro Ventures has a diverse portfolio that includes a variety of companies in the biomedical technology sector. Notable portfolio companies include:
Moses Chen, Ph.D. - Managing Partner. Moses has extensive experience in biomedical investments and has led numerous successful funding rounds in the sector.
Francis Chung, Ph.D., MBA - Managing Partner. Francis combines his scientific background with business acumen, focusing on strategic investments in healthcare.
Alex Chen, MS, MBA - Managing Partner. Alex brings a wealth of knowledge in operational management and investment strategies within the biomedical field.
Aimee Chen, MS - Partner, General Manager China. Aimee oversees operations in China, leveraging her expertise to expand Maxpro's reach in the region.
Pin I Wu, LL.M. - Manager. Pin specializes in legal and regulatory aspects of biomedical investments, ensuring compliance and strategic alignment.
Claudia Huang, Ph.D. - Assistant Vice President. Claudia focuses on portfolio management and supports companies in their growth trajectories.
Ying Chen, MS - Assistant Vice President. Ying works closely with portfolio companies, providing operational support and strategic insights.
Huei-Ling Liu, Ph.D. - Manager. Huei-Ling contributes her scientific expertise to evaluate potential investments and support portfolio companies.
To pitch Maxpro Ventures, founders should send their business plans to BP@maxproventures.com. The pitch deck should include a comprehensive overview of the business, including the problem being addressed, the solution offered, market analysis, and team qualifications. A clear financial projection and funding requirements are also essential.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, but cold emails are also accepted if the proposal is compelling.
In 2023, Maxpro Ventures continued to expand its portfolio, adding several innovative companies in the biomedical sector. Notable investments include companies focused on next-generation therapies and advanced medical devices.
The firm has also been active in supporting its existing portfolio companies, providing strategic guidance and resources to help them navigate market challenges. This ongoing support has been crucial for companies looking to scale and achieve their milestones.
What are Maxpro Ventures' investment criteria?
Maxpro Ventures focuses on breakthrough biomedical technology companies, particularly in next-generation cell and gene therapies, biologic drugs, medical devices, diagnostics, and healthcare services. They invest across various stages, from pre-seed to growth equity.
How can I pitch to Maxpro Ventures?
Founders can submit their business plans via email to BP@maxproventures.com. It is recommended to include a detailed overview of the business model, market opportunity, and team background.
What makes Maxpro Ventures different from other investors?
Maxpro Ventures combines capital investment with strategic guidance, leveraging the expertise of its team to accelerate the development of portfolio companies. Their focus on the biomedical sector allows them to provide specialized support.
What is the geographic scope of Maxpro Ventures?
The firm invests globally, targeting innovative healthcare solutions from various regions. This global approach enables them to tap into diverse markets and technologies.
What is the typical check size for investments?
While specific check sizes are not disclosed, Maxpro Ventures invests across multiple stages, indicating a flexible approach to funding that can accommodate varying capital needs.
What kind of post-investment involvement does Maxpro Ventures have?
Maxpro Ventures provides ongoing support to its portfolio companies, offering strategic guidance and resources to help them navigate challenges and scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.